🟢 Cybin is trading 6.6% up today on Phase 3 depression trial progress and $50M equity raise

Cybin is trading 6.6% up at $7.58 in pre-market, extending gains driven by optimism around its late-stage depression program.

• The company surpassed 86% enrollment in its APPROACH Phase 3 HLP003 trial for Major Depressive Disorder (MDD).
• A recent $50 million equity raise has significantly strengthened the company's cash position and funding runway.
• Market sentiment remains bullish on the MDD pipeline following these clinical and financial milestones.